The endothelium plays a central role in cardiovascular regulation. Endothelial cells produce a variety of vasculoregulatory and vasculotropic molecules that act locally or at distant sites. Alteration of the vascular endothelium is a primary event in the pathogenesis of vascular diseases, such as atherosclerosis, as well as systemic and pulmonary hypertension. For these reasons, the study of human endothelium has become central in cardiovascular research. Unfortunately, technologies handling endothelial cells in vitro are often criticized due to the uncertain transferability of results to intact organs and, importantly, to humans. Although methods to assess endothelial function non-invasively have been available for decades, cell-based approaches for the direct ex vivo evaluation of endothelial cell biology in humans have been devised only recently. The discovery of endothelial progenitor cells opened the way for studies on vascular regeneration, while it has been recognized that mature circulating endothelial cells mainly represent a consequence of the ongoing vascular damage. Coupled with a minimally invasive way to obtain fresh human endothelial cells through an endovascular biopsy, these new methods provide a novel outlook on human endothelial cells as close as possible to their natural environment. In this review, we will summarize the current knowledge and the methodological perspective of these cell-based methods.
Endothelial cell biology and pathology
Once viewed as a passive inner cover of the vessel wall, the endothelium is now recognized as an active organ with many important functions, such as regulation of vascular tone and permeability, coagulation, inflammation, and angiogenesis. For this reason, the assessment of the endothelium has progressively become a cornerstone of modern cardiovascular research. 1 Endothelial cells are flat-shaped, have central elongated nuclei, and are about 1-2 mm thick and 10-20 mm in diameter. They produce a number of vasoactive substances that can mediate either vasoconstriction (e.g. endothelin-1) or vasodilation [e.g. nitric oxide (NO)]. Endothelial cells are exposed to a variety of nutritive and toxic substances carried by the bloodstream, thus being easily subject to pathological alterations. 2 The term endothelial dysfunction refers to a condition in which the endothelium loses its physiological properties; the tendency to promote vasodilation, fibrinolysis, and antiaggregation is lost and the opposite effects take place. 3 It is widely accepted that the most important mechanism leading to endothelial dysfunction is the reduced bioavailability of NO. This gas is derived from L-arginine through a reaction catalysed by a family of enzymes, called the endothelial NO synthases (eNOS). 4 NO diffuses from endothelial cells to vascular smooth muscle cells and activates NO-sensitive guanylyl cyclase, leading to the conversion of GTP to cGMP, which in turn induces relaxation by modifying intracellular calcium concentrations. Reduction in NO bioavailability can result from a defective eNOS expression/activity or from an excessive NO degradation, usually through an interaction with superoxide (O 2 2 ), that generates peroxy-
nitrites (ONOO 2
. 5 Indeed, oxidative stress is considered one major cause of endothelial dysfunction. eNOS is also the master gene regulator of endothelial cells that orchestrate cell phenotype, function, and survival. Indeed, endothelial dysfunction can be associated with apoptosis of endothelial cells, which tend to detach from the vessel wall, leaving a thrombogenic and pro-inflammatory subendothelial surface. 6 Endothelial damage is considered the first step of vascular remodelling taking place during the development of atherosclerosis in the systemic circulation and of pulmonary hypertension in the pulmonary circulation. 7, 8 Unfortunately, the endothelium has a limited ability to repair itself, and therefore, ways to prevent or counter endothelial dysfunction/damage are actively pursued. This kind of research needs reliable methods to assess the anatomical and functional integrity of the endothelium. Although this can be easily explored in animals, it is much more difficult to have direct information on endothelial biology in humans. Endothelial function is usually assessed non-invasively as the NO-dependent vasodilatory capacity of a given arterial segment to an endothelial stimulus, such as shear stress [e.g. flow-mediated dilation (FMD)] or acetylcholine. 9 However, this measure is subjected to intrapatient variability, confounding effects of concomitant therapies, and cannot distinguish between functional and anatomical alterations. 10 Other clinical indicators of endothelial dysfunction are represented by molecules that circulate in the bloodstream, such as ICAM-1, VCAM-1, vWf, and thrombomodulin, indicating pathological activation of the endothelium in the setting of a chronic low-grade inflammatory state.
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In addition, once a subject is diagnosed with endothelial dysfunction, it is quite difficult to explore the underlying biochemical mechanisms. As a surrogate of the human endothelium, most researchers use cultured human endothelial cell lines, which allow extensive and detailed biochemical studies and manipulations. However, uncertainties always remain regarding the transferability of results obtained in vitro to the in vivo clinical picture. 12 Taken together, these observations emphasize the need for more direct ex vivo approaches to study the human endothelium in a condition as close as possible to its in vivo natural environment. In this review, we will discuss three relatively new cell-based methods to study endothelial cells [circulating endothelial cells (CECs), circulating endothelial progenitor cells (EPCs), and endothelial biopsy) with the aim of providing some indications for a comprehensive evaluation of endothelial biology in humans.
Circulating endothelial cells
Mature endothelial cells circulate in the bloodstream at a very low concentration. The exact origin of these CECs is presently not entirely defined. It is believed that they are derived from the vessel wall itself, by sloughing of resident endothelial cells into the circulation, as part of their normal turnover process, or as an effect of damaging factors, either mechanical (e.g. high blood pressure) or chemical (e.g. high glucose). 13 The existence of CECs in the bloodstream was first described by Hladovec 14 in 1978, who observed a phenomenon called endothelialaemia after exposing rats to endotoxin, hyaluronidase, streptokinase, anoxia, and vasoactive drugs. In more recent times, the clinical and pathophysiological meaning of these cells has gained renewed attention. Resident endothelial cells might detach from the vessel wall as viable integral cells or as cell fragments. As a result, CECs often display features of apoptotic cells, such as externalization of phosphatidylserine and binding of the early apoptotic marker Annexin-V, or frank evidence of cell death, such as loss of plasma membrane integrity and propidium iodine staining. 15 It is not clear whether CECs may also derive from sites of incompetent angiogenesis, where tissue endothelial cells proliferate and organize into immature leaky tubular structures that come into contact with the bloodstream. 16 Regression of these embryoid structures is expected to produce an increase in the number of CECs. Moreover, enhanced release of CECs might also take place during normal body growth or at sites of tissue regeneration, either physiological (e.g. after menstruation) or pathological (e.g. wound healing). In normal steady-state conditions, the amount of CECs in the bloodstream is very low, due to the fact that endothelial turnover is a very slow process in the absence of pathological stimuli and that non-viable CECs are likely rapidly cleared by the reticulo-endothelial system. The level of CECs is expected to increase as a consequence of any type of damage to the vessel wall. 17 Indeed, several studies have demonstrated an increased CEC level in patients with numerous clinical conditions characterized by vascular involvement, ranging from cardiovascular risk factors (e.g. diabetes mellitus), 18 immune-mediated vasculitides, 19 cancer, 16 and sickle cell disease crisis 20 to vasculotrophic infectious diseases. 21 Based on this background, the level of CECs can be taken to represent an indicator of the ongoing systemic endothelial damage. Obviously, CEC measure cannot distinguish where the cells come from and therefore the site of endothelial damage, e.g. coronary arteries or the peripheral circulation. Anyway, a high CEC level, for instance, in the setting of acute coronary syndrome, has been shown to identify subjects at higher risk for subsequent cardiovascular events. 22 From a methodological standpoint, CECs were originally isolated and quantified by immunomagnetic bead selection. This method is based on the incubation of blood cells with dynabeads conjugated to an anti-endothelial antibody, such as anti-CD146. After this isolation and enrichment protocol, CEC identity should be confirmed and CECs were identified as nucleated cells with a larger diameter of at least 10 mm, which bind more than five beads and stain positive for Ulex Europeus lectin (UEA-1, in humans) and CD146. 23 The sole positivity for CD146 cannot be regarded as specific for endothelial cells, as it has been subsequently demonstrated that a subset of activated T-lymphocytes express CD146. 24 In addition, CD146 has been shown to be expressed on a subpopulation of immature CECs or endothelial progenitors (see below). 25 Literature recommendations to improve sensitivity and specificity of this immunomagnetic approach include the use of whole blood instead of Ficoll or other leuco-concentrated preparations, immediate processing (during eventual delay in processing, up to 24 h, the sample should be stored at 48C), and the use of an Fc-blocking reagent to saturate sites for unspecific binding of the bead-conjugated antibodies. 23 Limitations of this method are mainly related to the suboptimal yield of CECs due to the incomplete separation of the cells of interest from the rest of circulating blood cells. In addition, the enumeration of CECs fulfilling the above-described criteria requires time-consuming microscopic inspection and is not automated. More recently, immunomagnetic bead isolation has been almost completely replaced by a flow cytometry approach that can be fully standardized and automated. 26 The flow cytometry protocol is based on a mononuclear cell analysis for size, nuclear complexity, and binding of specific antibodies conjugated to given fluorochromes. After excluding cell debris with a morphological gate, cells are stained with the panleucocyte antigen CD45 to exclude haematopoietic cells and with a nuclear dye (e.g. Syto16) and CD31 to exclude platelets (which appear as non-nucleated CD31 + events). The remaining cells are assayed for the expression of the endothelial antigen CD146 (in this case, contamination by T-lymphocytes is ruled out by CD45 negativity). Finally, a negative staining for CD133 can distinguish between CECs and differentiating EPCs, which might express CD146. 25 Mancuso et al. 26 have performed electron microscopy imaging on
+ cells isolated by a fluorescenceactivated cell sorter and found that these cells are indeed nucleated, viable, and contain the endothelial-specific Weibel-Palade bodies. In addition, they have shown by a molecular biology approach that these cells express vascular endothelial (VE)-cadherin mRNA. Using this standardized protocol, the authors were able to show a low intra-observer variability (4% for fresh samples and 12% for frozen samples) and an acceptable inter-observer variability (17% for fresh samples and 16% for frozen samples). Thus far, these evidences support the use of the Syto16
+ staining to identify CECs, even if a systematic comparative study vs.
Ex vivo endothelial research other antigenic combinations has not yet been performed. Despite the many advantages of flow cytometry over immunomagnetic bead selection, it should be recognized that no single marker can unambiguously identify CECs. Indeed, unless an extensive preliminary characterization and standardization of the method is performed, CECs might be difficult to distinguish from EPCs (which share endothelial antigens and some morphological characteristics), endothelial microparticles (EMPs) (which express endothelial antigens but are smaller, see below), platelet microparticles (which express CD31 and vWf), and even from immune cells (which can display similar morphological aspects and transiently express some endothelial antigens) ( Table 1) . Notwithstanding these limitations, it appears that the methods to analyse CECs have been substantially improved over the last years and that a reliable approach is available, based on flow cytometry. It should be, however, noted that a considerable amount of work is usually needed to achieve a good standard in each laboratory and that the learning curve can be long and demanding. It has been mentioned that endothelial cell damage can also result in the detachment of endothelial cell fragments, which are called EMPs. Although it is not clear whether EMPs derive directly from the vessel wall or by fragmentation of CECs, their formation results from the vesiculation of the plasma membrane during either cell activation or apoptosis. EMP membranes consist of lipids and proteins, whereas EMP content varies according to the generation process and the cells of origin. 27 Circulating EMP levels can be assayed by ultracentrifugation followed by flow cytometry analysis of plateletpoor plasma. Endothelial identity is based on CD31 or CD144 expression, whereas particle size is determined by comparison with control beads; further, Annexin-V staining helps in distinguishing apoptotic microparticles. 28 It has been shown that EMPs are elevated in many conditions of high cardiovascular risk, such as hypertension, 29 diabetes, 30 dyslipidaemia, 31 and chronic renal failure. 32 The presence of circulating EMPs conveys a similar biological meaning as the presence of CECs, that is, continuous low-grade endothelial turnover, whereas an increased amount of EMPs would reflect the ongoing endothelial damage. However, besides being a passive consequence of vascular damage, there is growing evidence that EMPs are actively involved in cardiovascular biology, due to the fact that they carry biological information in the form of lipid signalling molecules, proteins, and enzymes. EMP can impact negatively on cardiovascular biology, for instance, by stimulating inflammation, endothelial adhesiveness, and thrombosis. 33 -35 By converse, EMP might even transport protective signals: EMPs derived from ischaemic muscles have been shown to exert a favourable effect on post-ischaemic revascularization. 36 Thus, it remains to be established whether EMPs play a causal pathogenic role or they are a temptative compensatory effect of cardiovascular disease. Future studies in this evolving field will help elucidating this issue.
Circulating endothelial progenitor cells
EEPCs were discovered in 1997 by Asahara et al. 37 as cells migrating from the bone marrow into the peripheral circulation and being able to differentiate into mature endothelial cells in vitro and in vivo. These cells were initially identified by the surface expression of the stem cell antigen CD34 or the endothelial antigen KDR (VEGFR-2). Many subsequent studies have shown two important functions of EPCs in the cardiovascular system: regeneration of the endothelial layer and formation of new blood vessels. In addition, the measure of circulating EPCs by flow cytometry provides an index of cardiovascular risk. From a methodological standpoint, there are two main methods to study EPCs. 38 Pure quantitative data can be obtained by the quantification of circulating EPCs using flow cytometry, whereas qualitative and functional data require isolation of the cells in culture. Flow cytometry quantification of EPCs is based on the analysis of cell surface expression within the mononuclear cell gate. EPCs should express at least one immaturity/stem cell antigen (e.g. CD34 or CD133) plus at least one endothelial antigen (usually KDR or CD31 Cell culture techniques used to isolate EPC are not standardized (the reader can refer to one excellent review in the literature regarding this issue). 42 In addition, ex vivo culture of EPC requires the extrapolation of the cells from their natural environment for a certain period, depending on the culture protocol. This means that results obtained with cultured EPCs might not closely reflect in vivo pathophysiological mechanisms and suffer from similar limitations as culture of endothelial cells lines. It should be noted that some of the short-term (4 -7 days) protocols used to isolate EPC in culture (likely including the method used by Asahara et al.
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) do not allow the selection of an endothelial cell population, but yield a heterogeneous population of cells including monocytes/macrophages and Tlymphocytes, assuming a spurious endothelial-like phenotype. 43, 44 Even if these cells might have some endotheliotrophic properties and stimulate vascular repair and angiogenesis, they should not be referred to as EPCs. For these reasons, some authors have coined the terms 'monocytic' or 'early' EPCs or 'circulating angiogenic cells' or 'circulating vasculogenic cells'. Another short-term protocol allows the isolation of the so-called CFU-Hill, which are similar to early/monocytic EPCs. 45 By converse, a prolonged cell culture protocol (≥14 days) in a supplemented endothelial differentiation medium yields the isolation of a purer population of cells displaying a full endothelial phenotype, which can be referred to as 'late' EPCs. 38 Late EPCs should be negative for leucocyte antigens (e.g. CD45 and CD14) and express high levels of stem cell markers (e.g. CD34) while assuming endothelial properties (morphology, expression of endothelial antigens, and eNOS). Moreover, the demonstration of an actual integration of isolated cells into host endothelium when transplanted in an animal model of ischaemia can be an additional criterion helping investigators to define late EPCs. Various methodologies are ingenerating confusion in the literature and the use of different methods can yield even opposite results when investigating the same disease or biological process. 46, 47 Detractors of the EPC isolation protocols argue that most of the available literature should be critically revisited in light of the recent observation that claimed EPCs have neither progenitor nor endothelial properties. Once the late EPCs have been isolated, they can be used for biochemical studies or response to various stimuli. The EPC culture is also amenable to functional evaluations that simulate EPC activities in vivo. For instance, the ability of EPCs to expand and form colonies in culture would reflect the response to growth factors released locally after vascular damage or tissue ischaemia. Adhesion is a further step required for both re-endothelization and angiogenesis: it is assessed as the ability of EPCs to adhere to a monolayer of mature endothelium in culture. Migration of EPCs through the extracellular matrix is crucial for the growth of new vessels and can be evaluated in vitro as the ability to invade a Boyden-like chamber. Finally, the ability of EPCs to form vascular structures can be assessed with a tube formation assay in vitro or explored using an in vivo angiogenesis assay. EPCs represent a pool of circulating cells able to form a patch at sites of endothelial discontinuity, thus re-instituting the normal anatomical integrity of the vessel wall. This has been demonstrated extensively in animal models, albeit using different isolation methods. After induction of an experimental mechanical endothelial injury, healing of the endothelial layer can be monitored by histology or Evan's blue staining. He et al. 48 showed in rabbits that infusion of early EPCs significantly improved the extent of endothelial healing and also promoted the recovery of a normal vasodilatory response to acetylcholine, a typical measure of endothelial function. Moreover, when the cells were labelled in red with a fluorescent dye, the authors were able to show that EPC actually homed to sites of endothelial damage. While this study used exogenous EPCs, conceptually similar results were obtained by Werner et al. 49 using GFP bone marrow transplantation to follow the fate of endogenous EPCs. These observations indicate that EPCs are directly involved in the regeneration of a damaged endothelium, promoting restoration of both anatomical and functional integrity. In light of the ability of these cells to repair the endothelium, it is conceivable that in any given moment, the level of circulating EPCs reflects the endothelial endogenous regenerative capacity of a patient. Indeed, we and others have demonstrated that a correlation exists between circulating CD34 + KDR + EPCs quantified by FACS and endothelial function, measured as the brachial artery FMD. 50, 51 Other authors have shown a correlation between early cultured EPCs or CFU-Hill EPCs and FMD. 45, 52 Thus, unlike CECs, EPCs are considered to be vasculoprotective, and a general inverse correlation is believed to exist between CEC levels and EPC levels (Figure 1) , 53 even if EPCs were determined on the basis of the sole expression of KDR. 54 It should be also emphasized that whereas CECs are mainly innocent markers of vascular damage, EPCs are considered to be causally related to endothelial integrity. According to the response to injury hypothesis, endothelial damage is the first step in the atherogenetic process. 7 Thus, by directly promoting endothelial integrity, EPCs might prevent or at least delay the development of an atherosclerotic plaque at arterial sites prone to damage. In support of a role for bone marrow-derived EPCs in the prevention of atherogenesis, one study showed that chronic treatment of young apoE knockout mice with bone marrowderived cells cultured from young non-atherosclerotic apoE knockout mice or wild-type mice prevented the development of atherosclerotic lesions. 55 However, when the transplantation of bone marrowderived cells is performed later in the natural course of the disease in mice which already have advanced lesions, they are not able to prevent further atherosclerotic remodelling and can even lead to worsening features of atherosclerotic plaque, probably due to intraplaque angiogenesis. 56, 57 Clinically, we have demonstrated that circulating CD34 + KDR + EPCs are significantly reduced in healthy subjects with an increased carotid intima-media thickness, a sign of early atherosclerotic remodelling, beyond risk factors and C-reactive protein. 58 Moreover, in both the diabetic and non-diabetic population, CD34 + KDR + EPCs were shown to be progressively reduced with increasing severity of atherosclerotic disease. 59, 60 Similarly, EPCs might prevent the adverse vascular remodelling occurring after mechanical vascular damage. In animals, transplantation of early cultured EPCs has been shown to inhibit intimal hyperplasia induced by a mechanical endothelial denudation, resembling the pathological process occurring in patients who develop excessive neointima after positioning of a coronary stent. 48 As a clinical counterpart of this observation, some investigators have reported that a low level of early cultured EPCs at baseline predicts restenosis after coronary intervention. 61 However, this finding has not been reproduced in all studies. On the contrary, some studies also suggest that high levels of circulating EPCs, acutely mobilized from the bone marrow, might even represent the stimulus for excessive growth of intimal cells Another important function of EPCs is the ability to support angiogenesis or vasculogenesis. Whereas angiogenesis means the formation of blood vessels by spouting from the existing vasculature, vasculogenesis refers to the de novo vascular development within a previously avascular tissue. Studies in animals using genetic cell tracking have described in detail that the processes occurring during neovasculogenesis require the prominent contribution of bone marrow-derived cells, migrating through the tissue, organizing in tubules that eventually develop into mature vessels that come into contact with the bloodstream. 64, 65 However other research groups, using similar approaches, found that EPCs take part in the processes of angiogenesis as well, 66 although the quantitative contribution of the cells is debated. 67 -69 Indeed, several authors have reported that when infused or injected into an ischaemic tissue, EPCs locate at sites of ischaemia and promote the expansion of the microvascular network, but they rarely integrate into the host circulation. 70 This is especially true for early EPCs, while late EPCs might be able to form entire perfused blood vessels. 71 We found that tissue EPCs, derived from late cultured human cells, can remain in a quiescent state in the perivascular space, whence they can be activated by ischaemia and integrate into the vasculature, especially at branching sites. 72 Given the low physical integration of EPCs, it has been suggested that these cells support angiogenesis indirectly, by the secretion of growth factors and cytokines, such as VEGF and SDF-1a. 73 Regardless of the mechanisms, EPCs were shown to stimulate angiogenesis in many experimental settings, such as myocardial and skeletal muscle ischaemia, 51, 74 retinal ischaemia, 75 cancer, 76 endometrial regeneration, etc. 77, 78 The clinical counterpart of these observations is the direct relationship between the EPC (either early cultured, CFU-Hill, or circulating CD133 + KDR + cells) and the degree of coronary collateralization measured invasively in patients with coronary artery disease. 79, 80 Taken together, these data indicate that EPCs play two very important functions in the cardiovascular system: re-endothelialization and collateralization. Owing to these activities, EPCs are now considered an integrated component of the cardiovascular apparatus that are susceptible to pathological alterations as well as therapeutic modulation. Despite profound methodological differences among studies, EPCs appear to be consistently reduced or functionally impaired in the setting of virtually all risk factors for cardiovascular disease, 40, 81 such as diabetes, 82 smoking, 83 dyslipidaemia, 84 and hypertension. 85 Currently, it is believed that impairment of EPCs by high glucose, oxidized lipids, or angiotensin-II is one of the mechanisms that link risk factors to vascular disease. Interestingly, EPC can also be targeted by available drugs and may even represent pharmacological targets for novel compounds. Even if a detailed description of the therapeutic modulation of EPCs goes beyond the aims of the present article, it is worth citing that statins, angiotensin-converting enzyme-inhibitors, angiotensin receptor blockers, insulin, glitazones, erythropoietin, and oestrogens have been shown to positively modulate EPC number and/or function. 86 In conclusion, sophisticated methods have become available to study EPCs as a mechanism of vascular repair and regeneration, with a possibility to obtain pure quantitative data or functional information. The measure of circulating EPC by flow cytometry is to be considered a more direct window on endothelial regenerative potential than EPC culture, which requires extrapolation from the natural environment.
Endothelial biopsy
In the last decade, an additional method to study ex vivo patient's endothelial cells has become available. In 1999, Feng et al. 87 first described a method to sample endothelial cells using an endovascular Figure 1 Cell-based methods for the estimation of endothelial damage and repair. The measure of EPCs is meant to provide an estimate of the endothelial regenerative capacity, whereas the CEC level, especially if apoptotic, is taken to represent a marker of the ongoing vascular damage.
The balance between these two factors provides an index of endothelial health.
G.P. Fadini and A. Avogaro approach. They aimed at harvesting viable vascular endothelial cells in order to analyse gene expression at the sites of vascular damage. To this end, they used a coaxial curved stainless steel guide wire in patients undergoing routine endovascular procedures, which was moved forth and back touching the vessel wall to sample the endothelium under a J-shaped tip. Once removed from the guide, the tip of the wire was transferred to a lab tube and treated with a dissociation buffer to release the attached cells (Figure 2) . The authors demonstrated that this procedure allows safe isolation of patient's derived cells that were assessed for viability in terms of membrane integrity, energy-dependent uptake of acetylated low density lipoproteins, and cellular response to lipopolysaccharide. Endothelial identity was verified by immunoreactivity for endothelial antigens, such as vWf, thrombomodulin, and angiotensin-converting enzyme, and by mRNA expression of E-selectin, VCAM-1, and ICAM-1. About 250 endothelial cells could be harvested from each procedure, 20 -30% of which proved to be viable. This study casts the basis for a more comprehensive evaluation of the potential data that can be drawn from patient's own endothelial cells. The procedure of vascular endothelial sampling could be considered in patients undergoing routine endovascular diagnostic procedures or treatments (e.g. coronary angiography): the discharge material attached to the pigtail wire might be a valuable source of information. This condition bears the obvious advantage of having an easy and ethically sustainable access to the relevant arterial circulation in patients at risk for or with vascular disease. However, it would suffer from a lack of standardization in the sampling procedure, depending upon the site, type, and duration of catheterization, such that the retrieved material is likely to be heterogeneous among cases. To overcome this limitation, sampling should be performed after completion of the routine procedure, with a standardized advancement and pulling of the J-shaped wire within the arterial segment of interest, thus subjecting the patient to an additional wire insertion. Endothelial sampling could even be performed in healthy subjects for research purposes only: while ethical issues may arise when trying to access the coronary circulation, this could be done in the radial/brachial arteries in a relatively safe condition. However, regional differences in endothelial cell biology should be taken into account when interpreting data derived from endothelial cells sampled in a surrogate site and caution should be paid in transferring the same conclusion to other district, such as the coronary circulation. 88, 89 Obviously, there is an abundant possibility to sample the venous endothelium, as superficial vein catheterization is routinely performed in human research. Data derived from venous endothelial sample could be used to study conditions such as idiopathic venous thrombosis, but might be less relevant in the study of atherosclerosis, as long as a similar behaviour is not definitely demonstrated for venous and arterial endothelial cells. Colombo et al. 90 provided a further characterization of this methodology, combining a collection of 200-1000 endothelial cells from a superficial forearm vein or the radial artery, with reliable measurements of protein expression by quantitative immunofluorescence analysis. Quantitative immunofluorescence is a relatively uncommon methodology in endothelial cell research because investigators usually have a large amount of available cells in culture to perform biochemical measurements by western blot. That is why the authors validated the approach used for patient's own endothelial cells vs. immunoblot in culture cells. They also showed important similarities and differences between venous and arterial cells: nitrotyrosine level, NF-kB nuclear translocation, and COX-2 expression were similar in the arterial and the venous endothelium (and there was a correlation between the two), whereas eNOS expression was significantly greater in the arterial compartment, without a -v correlation. Interestingly, in five patients with advanced chronic heart failure, COX-2 expression in venous endothelial cells was significantly higher than in control subjects, suggesting that venous cells as well might be informative of endothelial cell alteration during advanced cardiovascular disease with systemic involvement. Using the same methodology, Donato et al. 91 found that endothelial dysfunction, measured as Ex vivo endothelial research reduced brachial artery FMD, was significantly and inversely correlated with the levels of nytrotyrosines and directly correlated with nuclear NF-kB in patient's own endothelial cells sampled from the brachial artery. Thus, the authors were able to demonstrate for the first time with a direct approach that endothelial dysfunction associated with advanced age is characterized by increased endothelial cell oxidative stress and inflammation. Interestingly, they confirmed a similar behaviour of venous and arterial endothelial cells in terms of nytrotyrosine abundance and NF-kB expression. In another study using the method described by Colombo et al., 90 venous endothelial cells sampled from subjects with vascular disease had significantly higher expression of proatherosclerotic genes, such as early growth response gene product (Egr-1) and monocyte chemoattractant protein-1, confirming the potential validity of venous endothelial sampling in the study of cardiovascular disease. Unfortunately, it should be noted that this methodology is far from reaching a good standardization. Harvesting of more than 200 cells from each procedure might turn out to be an optimistic result: Yu et al. 92 have found less than 100 cells per patient, which manifested endothelial morphology and immunoreactivity for von Willebrand factor and CD31 with good viability, but low eNOS expression. This low yield may render obtaining a sufficient amount of RNA necessary for molecular analysis difficult. 93 In case this methodological limitation can be overcome, an approach coupling endothelial cell sampling from patients' own vessels with a quantitative measurement of atherosclerosis-related readouts would reveal as alternative or adjunctive to the biochemical pathway analysis in cultured endothelial cells.
Hypothetical experiment and conclusions
Based on the notions presented in this review, it is possible to describe a hypothetical study design for the comprehensive evaluation of human endothelial biology in the setting, for instance, of prediabetes. Pre-diabetic patients indeed suffer an elevated cardiovascular risk when compared with the general population, the causes of which are incompletely understood. 94 Let us identify a sample of 50 subjects with impaired glucose tolerance (IGT) and 50 healthy subjects with normal glucose tolerance (NGT as CECs, soluble markers, and venous endothelial biopsy, could be repeated in the post-prandial phase, which is specifically altered in IGT vs. NGT or after appropriate treatments. Based on this comprehensive protocol, the investigators would obtain information about endothelial function (FMD), damage (CECs), activation (soluble markers), regenerative capacity (EPCs), and biochemical pathways (biopsy) to be correlated with clinical phenotype (Figure 3) . To the best of our knowledge, such a study has not been conducted in any clinical setting, even though the related technology is available. It should be acknowledged that all these methods have strengths and weaknesses that need to be taken into account when designing a similar study protocol ( Table 2) . Notwithstanding these limitations, the complementary analysis of EPCs, CECs, and biopsy-derived patients' cells would provide novel interpretative data on endothelial pathology. For instance, elevated CEC levels may assume a different meaning in the presence of high EPC levels (likely a condition of acute damage with EPC mobilization) or low EPCs (a chronic condition of endothelial damage). In parallel, quantitative biochemical analysis of endothelial cells sampled from different sites would help identifying the pathogenic mechanisms at work.
In conclusion, up-to-date cell-based methodologies allow a comprehensive evaluation of endothelial cell biology in humans that, when correlated to available functional measurements and clinical data, would provide a novel perspective on the endothelium with pathophysiological and therapeutic implications. 
